ediGene: Presentation of Clinical Data Obtained with EndoTAG-1 for the Treatment of Pancreatic Cancer and with the Oncolytic Virus NV1020 for the Treatment of Metastasized Colorectal Carcinoma at the ASCO GI Meeting

MARTINSRIED/MUNICH, Germany, January 16, 2008--The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announces that the clinical data obtained with the drug candidate EndoTAG(TM)-1 will be presented at the ASCO GI (American Society of Clinical Oncology -The Gastrointestinal Cancers Symposium Meeting) in San Francisco. Professor Mathias Löhr, principal investigator of the phase II clinical trial of EndoTAG(TM)-1 for the treatment of inoperable pancreatic carcinoma, will give a lecture on the results obtained in this trial, which were published in October 2008. Mathias Löhr is professor of gastroenterology and hepatology at Karolinska Institutet, Stockholm, and Head of Molecular Gastroenterology at the German Cancer Research Center (DKFZ), Heidelberg. The selection of the EndoTAG(TM)-1 data for presentation at the ASCO GI meeting illustrates the interest in this drug candidate on the part of scientists.

The lecture "A phase II trial of cationic liposomal paclitaxel in combination with gemcitabine in patients with unresectable pancreatic cancer" will be given in the "Oral Abstract Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract" today, January 16, 2009 at 1:15-1:30 pm local time (22.15 CET). In addition, a poster presentation of the data will be given during the evening session.

Moreover Professor T.R. Reid (University of California, San Diego, USA) will present further clinical data regarding safety and efficacy from the trial CT1030 of the oncolytic virus NV1020 in patients with advanced colorectal cancer metastatic to liver, during a poster session which will take place on Saturday, January 17, 2009, from 7:00-8:15 am local time. This lecture is titled "Phase II study of an onkolytic Herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC)".

This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene® and EndoTAG(TM)-1 are registered trademarks of MediGene AG. These trademarks may be owned or licensed in select locations only.

- ends -

MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies. MediGene has several drug candidates in clinical development, including EndoTAG(TM)-1, which could offer substantial sales returns. In addition, the company has numerous projects in research and pre-clinical development and possesses innovative platform technologies. MediGene focuses on the research and development of novel drugs for the treatment of cancer and autoimmune diseases.

Contact
MediGene AG
Fax:+49 - 89 - 85 65 - 2920

Julia Hofmann / Dr. Nadja Wolf,
Public Relations,
Tel.: +49 - 89 - 85 65 - 3324
 
Dr. Georg Dönges,
Investor Relations,
Tel.: +49 - 89 - 85 65 - 2946
E-mail: investor@medigene.com

Posted: January 2009

View comments

Advanced Breast Cancer: Learn about treatments to improve quality of life. Click Here

Close
Hide
(web5)